Amyloid positron emission tomography with 18F‐flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer's disease
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Objective: To evaluate the contributions of amyloid‐positive (Am+) and medial temporal atrophy–positive (MTA+) scans to the diagnostic classification of prodromal and probable Alzheimer's disease (AD). Methods: 18 F‐flutemetamol‐labeled amyloid positron emission tomography (PET) and magnetic resonance imaging (MRI) were used to classify 10 young normal, 15 elderly normal, 20 amnestic mild cognitive impairment (aMCI), and 27 AD subjects. MTA+ status was determined using a cut point derived from a previous study, and Am+ status was determined using a conservative and liberal cut point. Results: The rates of MRI scans with positive results among young normal, elderly normal, aMCI, and AD subjects were 0%, 20%, 75%, and 82%, respectively. Using conservative cut points, the rates of Am+ scans for these same groups of subjects were 0%, 7%, 50%, and 93%, respectively, with the aMCI group showing the largest discrepancy between Am+ and MTA+ scans. Among aMCI cases, 80% of Am+ subjects were also MTA+, and 70% of amyloid‐negative (Am−) subjects were MTA+. The combination of amyloid PET and MTA data was additive, with an overall correct classification rate for aMCI of 86%, when a liberal cut point (standard uptake value ratio = 1.4) was used for amyloid positivity. Interpretation: 18 F‐flutemetamol PET and structural MRI provided additive information in the diagnostic classification of aMCI subjects, suggesting an amyloid‐independent neurodegenerative component among aMCI subjects in this sample.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jack, C. R., Lowe, V. J., Senjem, M. L., Weigand, S. D., Kemp, B. J., Shiung, M. M., Knopman, D. S., Boeve, B. F., Klunk, W. E., Mathis, C. A., et al. (2008) · Brain · doi:10.1093/brain/awm336 · Cited by 958
APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging
Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., & Mintun, M. A. (2010) · Annals of Neurology · doi:10.1002/ana.21843 · Cited by 830
Pike, K. E., Savage, G., Villemagne, V. L., Ng, S., Moss, S. A., Maruff, P., Mathis, C. A., Klunk, W. E., Masters, C. L., & Rowe, C. C. (2007) · Brain · doi:10.1093/brain/awm238 · Cited by 789 · cited 3×
“frequency of Am1 subjects in the aMCI group increased from 50% to the more commonly reported 60% level [3].”
BackgroundMethodEpisodic memory loss is related to hippocampal-mediated -amyloid deposition in elderly subjects
Mormino, E. C., Kluth, J. T., Madison, C. M., Rabinovici, G. D., Baker, S. L., Miller, B. L., Koeppe, R. A., Mathis, C. A., Weiner, M. W., Jagust, W. J., et al. (2009) · Brain · doi:10.1093/brain/awn320 · Cited by 684
Bobinski, M., de Leon, M. J., Wegiel, J., DeSanti, S., Convit, A., Saint Louis, L. A., Rusinek, H., & Wisniewski✠, H. M. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00476-5 · Cited by 455
Relationship between atrophy and β‐amyloid deposition in Alzheimer disease
Chételat, G., Villemagne, V. L., Bourgeat, P., Pike, K. E., Jones, G., Ames, D., Ellis, K. A., Szoeke, C., Martins, R. N., O'Keefe, G. J., et al. (2010) · Annals of Neurology · doi:10.1002/ana.21955 · Cited by 373
Convit, A., de Asis, J., de Leon, M. J., Tarshish, C. Y., De Santi, S., & Rusinek, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(99)00107-4 · Cited by 359 · cited 3×
“Among EN subjects, the importance of identifying MTA1 status is the knowledge that those in this group who later progress to MCI or AD are more likely to have smaller HP volumes (and therefore greater MTA scores) than those who do not progress [8,9,22,23].”
BackgroundNeuropathological basis of magnetic resonance images in aging and dementia
Jagust, W. J., Zheng, L., Harvey, D. J., Mack, W. J., Vinters, H. V., Weiner, M. W., Ellis, W. G., Zarow, C., Mungas, D., Reed, B. R., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21296 · Cited by 302
Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease
Reiman, E. M., Uecker, A., Caselli, R. J., Lewis, S., Bandy, D., De Leon, M. J., De Santi, S., Convit, A., Osborne, D., Weaver, A., et al. (1998) · Annals of Neurology · doi:10.1002/ana.410440226 · Cited by 266 · cited 1×
“Among EN subjects, the importance of identifying MTA1 status is the knowledge that those in this group who later progress to MCI or AD are more likely to have smaller HP volumes (and therefore greater MTA scores) than those who do not progress [8,9,22,23].”
BackgroundBrain structural alterations before mild cognitive impairment
Smith, C. D., Chebrolu, H., Wekstein, D. R., Schmitt, F. A., Jicha, G. A., Cooper, G., & Markesbery, W. R. (2007) · Neurology · doi:10.1212/01.wnl.0000259542.54830.34 · Cited by 161
Cited by
Suspected non-Alzheimer disease pathophysiology — concept and controversy
Jack, C. R., Knopman, D. S., Chételat, G., Dickson, D., Fagan, A. M., Frisoni, G. B., Jagust, W., Mormino, E. C., Petersen, R. C., Sperling, R. A., et al. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.251 · Cited by 306
Jack, C. R., Wiste, H. J., Weigand, S. D., Knopman, D. S., Mielke, M. M., Vemuri, P., Lowe, V., Senjem, M. L., Gunter, J. L., Reyes, D., et al. (2015) · Brain · doi:10.1093/brain/awv283 · Cited by 254
Using visual rating to diagnose dementia: a critical evaluation of MRI atrophy scales
Harper, L., Barkhof, F., Fox, N. C., & Schott, J. M. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-310090 · Cited by 187
Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease
Vandenberghe, R., Adamczuk, K., Dupont, P., Laere, K. V., & Chételat, G. (2013) · NeuroImage: Clinical · doi:10.1016/j.nicl.2013.03.014 · Cited by 99
“This could be partly explained by the overlap in hippocampal volumes between the AD group and the controls (Duara et al., 2012; Thurfjell et al., 2012).”
BackgroundSelf-citationSuspected non-AD pathology in mild cognitive impairment
Wisse, L. E. M., Butala, N., Das, S. R., Davatzikos, C., Dickerson, B. C., Vaishnavi, S. N., Yushkevich, P. A., & Wolk, D. A. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.08.029 · Cited by 78
Metadata
- Authors
- Duara, R., Loewenstein, D. A., Shen, Q., Barker, W., Potter, E., Varon, D., Heurlin, K., Vandenberghe, R., & Buckley, C.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2012-11-26
- Volume
- 9
- Issue
- 3
- Pages
- 295-301
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W1989476860
- Cited by
- 60
- References
- 10
- FWCI
- 4.10
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Amyloid positron emission tomography with 18F‐flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.jalz.2012.01.006
- The paper
- Duara, R., Loewenstein, D. A., Shen, Q., Barker, W., Potter, E., Varon, D., Heurlin, K., Vandenberghe, R., & Buckley, C. (2013). Amyloid positron emission tomography with 18F‐flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2012.01.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.